The Economic Value of CTL019 Therapy for Pediatric Patients with Relapsed and Refractory Acute Lymphoblastic Leukemia in the United Kingdom

被引：0
|
作者：
Snider, Julia
Brauer, Michelle
Hao, Yanni
Karaca-Mandic, Pinar
Tebeka, Mahlet Gizaw
Zhang, Jie
Batt, Katharine
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1330
引用
收藏
页数：2
相关论文
共 50 条
  • [1] CTL019 Clinical Pharmacology and Biopharmaceutics in Pediatric Patients with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
    Mueller, Karen Thudium
    Waldron, Edward
    Grupp, Stephan A.
    Levine, John
    Laetsch, Theodore W.
    Pulsipher, Michael A.
    Boyer, Michael
    August, Keith
    Hamilton, Jason
    Awasthi, Rakesh
    Sickert, Denise
    Chakraborty, Abhijit
    Levine, Bruce L.
    June, Carl H.
    Tomassian, Lori
    Leung, Mimi
    Taran, Tetiana
    Wood, Patricia
    Maude, Shannon
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S261 - S262
  • [2] CTL019 Therapy Appears Safe and Effective in Pediatric Patients with Down Syndrome with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia
    Laetsch, Theodore W.
    Maude, Shannon L.
    Grupp, Stephan A.
    Boyer, Michael W.
    Harris, Andrew C.
    Qayed, Muna
    Phillips, Christine L.
    Pulsipher, Michael A.
    Bittencourt, Henrique
    Wood, Patricia A.
    Mueller, Karen Thudium
    Weng, Yanqui
    June, Carl H.
    Levine, Bruce L.
    Hiramatsu, Hidefumi
    BLOOD, 2017, 130
  • [3] CTL019 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS IN PEDIATRIC PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Mueller, K. Thudium
    Waldron, E.
    Grupp, S. A.
    Levine, J.
    Laetsch, T. W.
    Pulsipher, M. A.
    Boyer, M.
    August, K.
    Hamilton, J.
    Awasthi, R.
    Sickert, D.
    Chakraborty, A.
    Levine, B. L.
    June, C. H.
    Tomassian, L.
    Leung, M.
    Taran, T.
    Wood, P.
    Maude, S. L.
    HAEMATOLOGICA, 2017, 102 : 178 - 179
  • [4] TISAGENLECLEUCEL (CTL019) THERAPY APPEARS SAFE AND EFFECTIVE IN PEDIATRIC PATIENTS WITH DOWN SYNDROME WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA
    Laetsch, Theodore
    Maude, Shannon L.
    Grupp, Stephan A.
    Boyer, Michael
    Harris, Andrew
    Qayed, Muna
    Phillips, Christine
    Pulsipher, Michael
    Bittencourt, Henrique
    Wood, Patricia
    Mueller, Karen Thudium
    Weng, Yanqiu
    June, Carl
    Levine, Bruce
    Hiramatsu, Hidefumi
    PEDIATRIC BLOOD & CANCER, 2018, 65
  • [5] CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
    Vairy, Stephanie
    Garcia, Julia Lopes
    Teira, Pierre
    Bittencourt, Henrique
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 3885 - 3898
  • [6] Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
    Mueller, Karen Thudium
    Maude, Shannon L.
    Porter, David L.
    Frey, Noelle
    Wood, Patricia
    Han, Xia
    Waldron, Edward
    Chakraborty, Abhijit
    Awasthi, Rakesh
    Levine, Bruce L.
    Melenhorst, J. Joseph
    Grupp, Stephan A.
    June, Carl H.
    Lacey, Simon F.
    BLOOD, 2017, 130 (21) : 2317 - 2325
  • [7] Cost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States
    Hao, Yanni
    Eldjerou, Lamis K.
    Yang, Hongbo
    Qi, Cynthia
    Globe, Denise
    BLOOD, 2017, 130
  • [8] Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
    Grupp, Stephan A.
    Laetsch, Theodore W.
    Buechner, Jochen
    Bittencourt, Henrique
    Maude, Shannon L.
    Verneris, Michael R.
    Myers, Gary D.
    Boyer, Michael W.
    Rives, Susana
    De Moerloose, Barbara
    Nemecek, Eneida R.
    Schlis, Krysta
    Martin, Paul L.
    Qayed, Muna
    Bader, Peter
    Hiramatsu, Hidefumi
    Mechinaud, Francoise
    Yanik, Gregory A.
    Peters, Christina
    Biondi, Andrea
    Baruchel, Andre
    Boissel, Nicolas
    Krueger, Joerg
    June, Carl H.
    Sen, Kapildeb
    Zhang, Yiyun
    Thudium, Karen E.
    Wood, Patricia A.
    Taran, Tetiana
    Pulsipher, Michael A.
    BLOOD, 2016, 128 (22)
  • [9] Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis
    Maude, Shannon L.
    Pulsipher, Michael A.
    Boyer, Michael W.
    Grupp, Stephan A.
    Davies, Stella M.
    Phillips, Christine L.
    Verneris, Michael R.
    August, Keith J.
    Schlis, Krysta
    Driscoll, Timothy A.
    Mody, Rajen
    Capitini, Christian M.
    June, Carl H.
    Levine, Bruce L.
    Wood, Patricia A.
    Yi, Lan
    Levine, John E.
    BLOOD, 2016, 128 (22)
  • [10] GLOBAL REGISTRATION TRIAL OF EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): UPDATE TO THE INTERIM ANALYSIS
    Buechner, J.
    Grupp, S. A.
    Maude, S. L.
    Boyer, M.
    Bittencourt, H.
    Laetsch, T. W.
    Bader, P.
    Verneris, M. R.
    Stefanski, H.
    Myers, G. D.
    Qayed, M.
    Pulsipher, M. A.
    De Moerloose, B.
    Hiramatsu, H.
    Schlis, K.
    Davis, K.
    Martin, P. L.
    Nemecek, E.
    Peters, C.
    Wood, P.
    Taran, T.
    Mueller, K. Thudium
    Zhang, Y.
    Rives, S.
    HAEMATOLOGICA, 2017, 102 : 178 - 178
12345